BARDA

Under Project BioShield, we're partnering w/ @VericelCorp to ensure access to FDA-licensed NexoBrid during a disaster. Vericel will manage product storage to guarantee availability & reduce costs, and further develop NexoBrid to treat blast injuries. medicalcountermeasures.gov/barda/cbrn

Building domestic manufacturing capacity, BARDA and Schott inaugurated a new production line for production of pharmaceutical glass vials at their facility in Lebanon, PA. Thanks to a longstanding partnership between @BARDA and Schott Pharma, the new production lines, once complete, will be used to make up to 140 million additional 2R vials annually and will support rapid scale production and delivery of medical countermeasures during emergencies.

We awarded a Project BioShield contract to @AVITAMedical for RECELL, an FDA-approved autograft-sparing device that uses a small sample of a patient’s own skin to treat full-thickness burns & trauma, enhancing readiness for radiological & nuclear incidents: ow.ly/AA7Z50Z9mT2

This #BARDAInnovation Spotlight highlights the Quic Liver + Kidney test being developed by @in_Diagnostics. Their test pairs with a smartphone app to assess organ health at home, enabling decentralized monitoring during both daily care and emergencies. 🔗: drive.hhs.gov/map/index.html

BARDA awarded a new Project BioShield contract to @ShionogiUS to enhance nat'l preparedness for biothreats and multidrug-resistant infections while expanding manufacturing to domestic facilities to build stronger defenses against future health emergencies: ow.ly/Uz1550YRbL1

@LumosDX @US_FDA This program's success demonstrates the value of collaborative #PublicPrivatePartnerships between the U.S. government and product development partners to combat antimicrobial resistance (#AMR). Learn more: medicalcountermeasures.gov/barda/fdaappro…

@LumosDX @US_FDA This rapid diagnostic can help determine if a patient’s acute respiratory infection is caused by a bacterial infection. It can also help inform treatment decisions and reduce unnecessary antibiotic use, which has the potential to improve #AntibioticStewardship. ⬇️

The FebriDx Bacterial/Non-bacterial Assay from @LumosDX is the 110th BARDA-supported product to receive @US_FDA approval, licensure or clearance. The 510(k) clearance & CLIA-waiver expands use of the test in settings like doctor’s offices, pharmacies, etc. ⬇️

BARDA's FASTx solicitation is back! We're funding #PlatformTechnologies that leverage #antiviral conjugates to develop therapeutics against filoviruses and other emerging threats. Learn more here: ow.ly/qv1u50YO4k0

We're advancing an AI-enabled assay from Ad Astra Diagnostics that produces results from a blood sample in less than 3 minutes. QScout CBC is designed to provide meaningful results to frontline providers in ambulances, urgent care centers, clinics & more: ow.ly/ugSS50YFbk1

We’re accepting proposals for a partner to lead the BARDA Accelerator Network Diagnostics and Medical Devices Hub! Submissions are due by 12PM ET on April 20, 2026. Learn more: ow.ly/74H550YEwG1

Today, there are no @US_FDA-approved broad-spectrum therapeutics to treat people with dengue, Zika, West Nile, and Chikungunya and other diseases caused by members of these viral families – but we’re working to change that. BARDA and VITAL, a BARDA Accelerator Network Hub, are partnering to offer prizes to the innovators who can develop novel broad-spectrum antiviral drugs that address this gap in the antiviral pipeline. aspr.hhs.gov/newsroom/Pages…

Together with @CompMedUCLA, we're furthering development of the SwabSeq Metagenomic Diagnostic Platform, designed to detect viral pathogens. It could serve as a rapid response tool to detect a novel respiratory virus in a #HealthSecurity emergency: medicalcountermeasures.gov/barda/dddi

We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral-priz…

Procuring #MedicalCountermeasures that are FDA-approved, licensed, and cleared can help ensure their availability in future health security emergencies. See more in our #CBRN portfolio here: medicalcountermeasures.gov/barda/cbrn

BARDA is bolstering national preparedness through the procurement of multiple #MedicalCountermeasures needed to protect the U.S. population from chemical, biological, radiological, and nuclear (#CBRN) threats.

Treatment courses of the oral suspension of @US_FDA-approved smallpox antiviral TEMBEXA (brincidofovir). This formulation fills a key preparedness gap for patients of all ages who are unable to swallow tablets.

Additional treatment courses of @Amgen’s Nplate, an @US_FDA-approved drug to treat the effects of acute radiation syndrome after a nuclear detonation. Amgen will maintain the product in vendor managed inventory for use in future emergencies.

@FluGenInc @OsivaxVaccines Current flu vaccines, while effective, may not address all variants that could emerge during an influenza pandemic. Therefore, broad-acting vaccines like these could protect against multiple strains and help bolster pandemic preparedness: medicalcountermeasures.gov/barda/influenz…

We’re partnering with @FluGenInc and @OsivaxVaccines to develop innovative #influenza vaccines, which could be used to address both pandemic and seasonal flu. If successful, these vaccines could help bolster national pandemic preparedness efforts.

@FluGenInc @OsivaxVaccines @OsivaxVaccines is developing OVX836, a next-generation, broad-spectrum vaccine. It is designed to provide long-lasting protection against both seasonal and pandemic #influenza A strains, allowing for a universal approach to vaccination during a flu pandemic.